吡拉西坦联合胞磷胆碱改善急性脑梗死后MCI的临床研究  

Clinical Study of Piracetam Combined with Citicoline to Improve MCI after Acute Cerebral Infarction

作　　者：彭勃 宋西珠 陈晓鹏[1] 史蓓蓓 曹韦[1] 李学忠[1] 陈思远 PENG Bo;SONG Xizhu;CHEN Xiaopeng;SHI Beibei;CAO Wei;LI Xuezhong;CHEN Siyuan(Department of Neurology,Affiliated People's Hospital of Jiangsu University,Zhenjiang,Jiangsu Province,212002 China;Department of Endocrinology,Affiliated People's Hospital of Jiangsu University,Zhenjiang,Jiangsu Province,212002 China)

机构地区：[1]江苏大学附属人民医院神经内科,江苏镇江212002 [2]江苏大学附属人民医院内分泌科,江苏镇江212002

出　　处：《中外医疗》2023年第17期119-123,共5页China & Foreign Medical Treatment

基　　金：镇江市第一人民医院科研基金(Y2019033);第二期“金山医者”医学领域人才培养计划(2022-JSYZ-18)。

摘　　要：目的研究吡拉西坦联合胞磷胆碱对急性脑梗死后轻度认知功能障碍(mild cognitive impairment,MCI的临床疗效。方法方便选取2021年9月—2022年9月江苏大学附属人民医院住院治疗的221例急性脑梗死后MCI患者,按照随机数表法分为观察组(n=105)、对照组(n=116)例。对照组除常规脑梗死内科治疗外均予以胞磷胆碱治疗,观察组在对照组基础治疗方案上加用吡拉西坦治疗。比较两组患者NIHSS、ADL、MMSE、MoCA评分变化及不良反应发生情况。结果治疗后,两组患者NIHSS评分均较治疗前降低,ADL、MMSE、MoCA评分均较治疗前提高,差异有统计学意义(P<0.05);治疗后,观察组MMSE、MoCA评分分别为(26.47±1.89)分、(24.31±1.97)分,明显高于对照组(24.41±2.31)分、(22.49±2.38)分,差异有统计学意义(t=7.211、6.156,P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论吡拉西坦联合胞磷胆碱对急性脑梗死后MCI有改善作用,且较为安全。Objective To study the clinical efficacy of piracetam combined with citicoline on mild cognitive impairment(MCI)after acute cerebral infarction.Methods 221 patients with MCI after acute cerebral infarction hospitalized in the People's Hospital Affiliated to Jiangsu University from September 2021 to September 2022 were conveniently selected and divided into the observation group(n=105)and the control group(n=116)according to the random number table.The control group was treated with citicoline in addition to conventional medical treatment for cerebral infarction,and the observation group was treated with Piracetam in addition to the basic treatment scheme of the control group.Compared the changes in NIHSS,ADL,MMSE,MoCA scores,and incidence of adverse reactions between two groups of patients.Results After treatment,the NIHSS scores of both groups of patients decreased compared to before treatment,while the ADL,MMSE,and MoCA scores increased compared to before treatment,the difference was statistically significant(P<0.05).After treatment,the MMSE and MoCA scores in the observation group were(26.47±1.89)points and(24.31±1.97)points,respectively,significantly higher than those in the control group(24.41±2.31)points and(22.49±2.38)points,the difference was statistically significant(t=7.211,6.156,P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Piracetam combined with citicoline has an ameliorative effect on MCI after acute cerebral infarction and is relatively safe.

关 键 词：吡拉西坦 胞磷胆碱 急性脑梗死 轻度认知功能障碍 

分 类 号：R741[医药卫生—神经病学与精神病学]